Amendment to the Specification:

Please amend paragraph 0041, page 14, as follows:

[0041] According to the present invention, the inventors take advantage of the ability of DNA methylation inhibitors, such as decitabine, reactivate the tumor suppressor genes silenced by aberrant hypermethylation. By reducing hypermethylation, these agents cancer render more effective anti-neoplastic agents whose pharmaceutical activity are adversely affected by hypermethylation in vivo.